Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Decreases By 16.6%

Keros Therapeutics, Inc. (NASDAQ:KROS) saw a large decrease in short interest in December. As of December 15th, there was short interest totaling 2,692,419 shares, a decrease of 16.6% from the November 30th total of 3,228,958 shares. Based on an average daily volume of 885,542 shares, the short-interest ratio is currently 3.0 days. Approximately 11.5% of the company’s stock are short sold. Approximately 11.5% of the company’s stock are short sold. Based on an average daily volume of 885,542 shares, the short-interest ratio is currently 3.0 days.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KROS. Oppenheimer restated an “outperform” rating and issued a $27.00 target price (up from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. Wedbush boosted their price objective on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday. Zacks Research raised shares of Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, November 7th. Finally, Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $21.38.

Keros Therapeutics Trading Up 0.8%

KROS stock traded up $0.16 on Wednesday, hitting $20.43. 58,109 shares of the company’s stock traded hands, compared to its average volume of 924,236. The stock has a market cap of $622.27 million, a price-to-earnings ratio of 13.26, a P/E/G ratio of 0.25 and a beta of 0.89. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $22.55. The stock has a fifty day moving average of $18.27 and a 200-day moving average of $15.96.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.93. The company had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The firm’s revenue was up 3585.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.41) earnings per share. On average, equities research analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Activity at Keros Therapeutics

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The disclosure for this sale is available in the SEC filing. Corporate insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL purchased a new position in shares of Keros Therapeutics during the 3rd quarter valued at $309,000. Jacobs Levy Equity Management Inc. increased its holdings in shares of Keros Therapeutics by 15.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 607,089 shares of the company’s stock worth $9,604,000 after purchasing an additional 82,749 shares during the period. Sherbrooke Park Advisers LLC acquired a new position in shares of Keros Therapeutics during the third quarter valued at about $176,000. Qube Research & Technologies Ltd raised its position in shares of Keros Therapeutics by 683.7% during the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after buying an additional 264,445 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its stake in shares of Keros Therapeutics by 58.8% in the third quarter. Public Employees Retirement System of Ohio now owns 41,453 shares of the company’s stock valued at $656,000 after buying an additional 15,350 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.